A Prospective Clinical Study of Phenylketonuria (PKU)

BioMarin Pharmaceutical

Status: Completed

Conditions: Phenylketonurias

Study type: Observational

Funder types: Industry

Identifiers

NCT04452513

307-902

Details and patient eligibility

About

This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.

Enrollment: 32 patients

Sex: All

Ages: 14+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female subjects with diagnosis of PKU which is a condition characterized by PAH deficiency
• Ability and willingness to maintain dietary protein intake consistent with baseline intake
• Willingness and capable per investigator opinion to comply with study procedures and requirements
• Plasma Phe Levels > 600umol/L

Exclusion criteria

• Clinically significant liver dysfunction or disease
• Prior treatment with gene therapy
• Any condition that, in the opinion of the investigator or Sponsor, would prevent the subject from fully complying with the requirements of the study